Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: 546C88; ANO-1020; BW546C88; L-NMMA; N-Monomethyl-arginine; NMA; TAI

Latest Information Update: 03 Sep 2009

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cornell Research Foundation; M. D. Anderson Cancer Center
  • Developer Arginox Pharmaceuticals
  • Class Antihypotensives; Basic amino acids; Diamino amino acids; Small molecules; Vascular disorder therapies
  • Mechanism of Action Nitric oxide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cardiogenic shock
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Cardiogenic shock; Hypotension; Kidney disorders; Rheumatoid arthritis; Septic shock; Transplant rejection

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 17 Nov 2006 Discontinued - Phase-II for Hypotension in United Kingdom (unspecified route)
  • 17 Nov 2006 Discontinued - Preclinical for Transplant rejection in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top